<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517893</url>
  </required_header>
  <id_info>
    <org_study_id>UM-DERM001</org_study_id>
    <nct_id>NCT01517893</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Simvastatin to Treat Generalized Vitiligo</brief_title>
  <official_title>A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators purpose is to initiate a phase II, randomized, placebo-controlled clinical
      trial to test simvastatin, an FDA-approved medication for hypercholesterolemia, as a new
      treatment for vitiligo. The aims of this placebo-controlled study seek to determine the
      safety and potential efficacy of simvastatin 80mg daily versus placebo in adult male patients
      with generalized vitiligo. Additionally, the investigators will collect blood to examine the
      effect of simvastatin on autoreactive CD8+ T cells in vitiligo patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in VASI Score</measure>
    <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
    <description>Number of participants with 33% decrease in the Vitiligo Area Scoring Index (VASI) from baseline to the last available study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in Investigator's Global Assessment Score</measure>
    <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
    <description>Increase in Investigator Global Assessment Scores of 30% or more from baseline to last available visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of High-dose Simvastatin Use in Vitiligo Patients.</measure>
    <time_frame>Assessed at every visit following randomization (monthly for 6 months)</time_frame>
    <description>Monitoring lab values and patient symptoms for evidence of simvastatin toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Sentinel Patch Area</measure>
    <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
    <description>Decrease in percent depigmentation of sentinel patch lesion from baseline to last available study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Quality of Life (QoL) Score</measure>
    <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
    <description>Increased quality of life based on end of study questionnaire scores of subjects randomized to treatment with simvastatin versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in CXCR3 Expression on CD8+ T Cells</measure>
    <time_frame>Assessed prior to treatment and periodically while on treatment</time_frame>
    <description>Determination of the effects of simvastatin treatment on CXCR3 expression in melanocyte-specific, autoreactive CD8+ T cells in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in Patient's Global Assessment Score</measure>
    <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
    <description>Increase in Patient's Global Assessment Scores of 30% or more from baseline to last available visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Among Various Outcome Measures for Vitiligo</measure>
    <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
    <description>Comparison of all tested outcome measures to identify the level of correlation among them, including VASI, Sentinel Patch, Investigator's Global Assessment Score, and Patient's Global Assessment Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Serum Chemokines</measure>
    <time_frame>Assessed prior to treatment and periodically while on treatment</time_frame>
    <description>Determination of the effects of simvastatin treatment on multiple chemokines in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male gender

          -  ages 18-64

          -  at least one vitiligo skin lesion measuring at least 2x2 cm in size

          -  willing and able to understand and sign informed consent

          -  able to complete study and comply with study procedures

        Exclusion Criteria:

          -  history of segmental vitiligo

          -  allergy to statin medications

          -  use of statin medications due to cardiac risks.

          -  use of any medications contraindicated with use of simvastatin

          -  use of topical vitiligo treatments in past 4 weeks

          -  use of laser or light-based vitiligo treatments within the past 8 weeks

          -  treatment with immunomodulating oral medications in the past 4 weeks

          -  use of statin medications in the past 8 weeks

          -  evidence of hepatic dysfunction, personal or family history of non-alcoholic steatotic
             hepatitis, or personal history of hepatitis

          -  evidence of renal dysfunction

          -  history of myopathy or rhabdomyolysis, or elevated baseline creatinine kinase

          -  recent history of alcohol or drug abuse

          -  history of diabetes

          -  untreated hypothyroidism

          -  other conditions that require the use of interfering topical or systemic therapy

          -  other current conditions that might interfere with study assessments such as, but not
             limited to, atopic dermatitis and psoriasis

          -  clinically significant abnormal findings or conditions which might, in the opinion of
             the Principal Investigator, interfere with study evaluations or pose a risk to subject
             safety during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Harris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School Clinical Research Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <results_first_submitted>February 19, 2015</results_first_submitted>
  <results_first_submitted_qc>March 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2015</results_first_posted>
  <last_update_submitted>March 18, 2018</last_update_submitted>
  <last_update_submitted_qc>March 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>John Harris</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vitiligo</keyword>
  <keyword>simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Arm</title>
          <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Arm</title>
          <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" lower_limit="28" upper_limit="55"/>
                    <measurement group_id="B2" value="39" lower_limit="32" upper_limit="49"/>
                    <measurement group_id="B3" value="41.6" lower_limit="28" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitiligo area scoring index</title>
          <description>The vitiligo area scoring index (VASI) is a measure of the surface area affected by vitiligo in a given research subject. It ranges from 0% (no vitiligo) to 100% (complete depigmentation of the entire body surface area). In terms of treatment, a decrease in VASI is desirable as it indicates less surface area affected by vitiligo. The score represents an estimate made by the investigators, based on the approximation that one &quot;hand unit,&quot; is roughly equivalent to 1% of the body surface area.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.81" lower_limit="3.23" upper_limit="40.93"/>
                    <measurement group_id="B2" value="23.09" lower_limit="5.12" upper_limit="46.26"/>
                    <measurement group_id="B3" value="19.23" lower_limit="3.23" upper_limit="46.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in VASI Score</title>
        <description>Number of participants with 33% decrease in the Vitiligo Area Scoring Index (VASI) from baseline to the last available study visit</description>
        <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in VASI Score</title>
          <description>Number of participants with 33% decrease in the Vitiligo Area Scoring Index (VASI) from baseline to the last available study visit</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Investigator's Global Assessment Score</title>
        <description>Increase in Investigator Global Assessment Scores of 30% or more from baseline to last available visit</description>
        <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of High-dose Simvastatin Use in Vitiligo Patients.</title>
        <description>Monitoring lab values and patient symptoms for evidence of simvastatin toxicity</description>
        <time_frame>Assessed at every visit following randomization (monthly for 6 months)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Sentinel Patch Area</title>
        <description>Decrease in percent depigmentation of sentinel patch lesion from baseline to last available study visit.</description>
        <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Quality of Life (QoL) Score</title>
        <description>Increased quality of life based on end of study questionnaire scores of subjects randomized to treatment with simvastatin versus placebo</description>
        <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in CXCR3 Expression on CD8+ T Cells</title>
        <description>Determination of the effects of simvastatin treatment on CXCR3 expression in melanocyte-specific, autoreactive CD8+ T cells in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
        <time_frame>Assessed prior to treatment and periodically while on treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Patient's Global Assessment Score</title>
        <description>Increase in Patient's Global Assessment Scores of 30% or more from baseline to last available visit</description>
        <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Among Various Outcome Measures for Vitiligo</title>
        <description>Comparison of all tested outcome measures to identify the level of correlation among them, including VASI, Sentinel Patch, Investigator's Global Assessment Score, and Patient's Global Assessment Score</description>
        <time_frame>Assessed at final study visit, 6 months after randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Serum Chemokines</title>
        <description>Determination of the effects of simvastatin treatment on multiple chemokines in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
        <time_frame>Assessed prior to treatment and periodically while on treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention Arm</title>
          <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <description>Sustained at work, unrelated</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>stool odor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>dental infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>leg twinge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>pulled muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>arthrlagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urine color change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John E. Harris, MD, PhD</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>508-856-1982</phone>
      <email>john.harris@umassmed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

